Every Form 4 that Verrica Pharmaceuticals Inc. (VRCA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VRCA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRCA filings page.
Verrica Pharmaceuticals Inc. (VRCA) reported that its Chief Operating Officer, David Zawitz, purchased 6,000 shares of common stock in an open-market or private transaction on 2026-08-17 at a weighted average price of $4.98 per share. Following this transaction, he directly holds 27,000 shares of Verrica common stock. The shares were bought in multiple trades at prices ranging from $4.90 to $5.00 per share.
Verrica Pharmaceuticals Inc. (VRCA) reported that its Chief Medical Officer, Noah L. Rosenberg, purchased common stock in two open-market or private transactions. On 2026-08-17, he bought 4,200 shares at a weighted average price of about $4.91 per share, and on 2026-08-18 he bought 2,030 shares at a weighted average price of about $4.92 per share. The prices for each trade reflect weighted averages of multiple executions between $4.90 and $4.95 per share.
Verrica Pharmaceuticals Inc. (VRCA) reported that CEO and President Jayson Rieger purchased common stock in the open market. On August 17, 2026, he bought 5,000 shares at $4.91 per share. On August 14, 2026, he bought 20,000 shares at a weighted average price of $5.06 per share, in multiple trades ranging from $5.04 to $5.088. He also reports 15 shares held indirectly by a child and additional shares held in separate family trusts, for which he disclaims beneficial ownership.
Verrica Pharmaceuticals Inc. (VRCA) reported that Interim CFO John J. Kirby purchased common stock in the open market. On 2026-08-18, he bought 5,000 shares at a weighted average price of $4.93 per share, in multiple trades priced between $4.85 and $4.99. After this transaction, he directly owns 23,962 shares of Verrica common stock.
Verrica Pharmaceuticals Inc. director Lawrence Eichenfield received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.04 per share and expire on June 4, 2036.
These options vest in 12 equal monthly installments beginning on July 5, 2026 and are expected to be fully vested by the next annual meeting of stockholders, assuming he continues to serve as a director through each vesting date. Following this award, he holds 16,000 derivative securities directly.
Verrica Pharmaceuticals Inc. director Diem Nguyen received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.04 per share and expire on June 4, 2036.
These options were granted as compensation and vest in 12 equal monthly installments beginning on July 5, 2026. They will in any event be fully vested on the date of the next annual meeting of stockholders, subject to Nguyen’s continued service as a director through each vesting date.
Verrica Pharmaceuticals Inc. director Mark A. Prygocki Sr. received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.0400 per share and represent equity-based compensation rather than an open-market purchase.
These options vest in 12 equal monthly installments beginning on July 5, 2026 and will in any event be fully vested by the date of the next annual meeting of stockholders, subject to his continued service as a director through each vesting date. Following this grant, he holds 16,000 derivative securities directly.
Verrica Pharmaceuticals Inc. CMO Noah L. Rosenberg received a grant of employee stock options for 233,840 shares of Common Stock. The options carry an exercise price of $8.21 per share and expire on December 23, 2035.
The grant was approved by a board committee on December 23, 2025, subject to shareholder approval of an amendment to Verrica's 2018 Equity Incentive Plan, which shareholders later approved on June 5, 2026. All 233,840 options are held directly and are compensation-related.
Vesting is performance-based: 50% of the options vest when the closing sales price on The Nasdaq Capital Market reaches at least $15.00 per share, and the remaining 50% vest when the price reaches at least $25.00 per share, subject to Rosenberg's continuous service through each vesting date.
Verrica Pharmaceuticals Inc. reported that Chief Operating Officer David Zawitz received a grant of employee stock options for 171,340 shares of common stock. The options have an exercise price of $8.21 per share and expire on December 23, 2035.
The grant was approved by a board committee on December 23, 2025, subject to shareholder approval of an amendment to the 2018 Equity Incentive Plan, which shareholders granted on June 5, 2026. Half of the options vest only if the share price reaches $15.00, and the other half vest if the share price reaches $25.00, in each case subject to Zawitz’s continuous service.
Verrica Pharmaceuticals CEO and President Jayson Rieger was granted an employee stock option covering 512,269 shares of common stock at an exercise price of $8.21 per share. The option expires on December 23, 2035 and vests in two tranches tied to share-price hurdles.
Half of the option vests if Verrica’s Nasdaq closing price reaches at least $15.00 per share, and the other half vests if it reaches at least $25.00 per share, in each case subject to his continued service. The grant was originally approved in December 2025 and became effective after shareholders approved an amendment to the 2018 Equity Incentive Plan on June 5, 2026.
Verrica Pharmaceuticals director Gavin Corcoran received a grant of stock options covering 16,000 shares of common stock at an exercise price of $6.04 per share. These options vest in 12 equal monthly installments beginning on July 5, 2026, and will be fully vested by the next annual stockholder meeting, subject to his continued service. Following this compensation award, Corcoran holds 16,000 stock options directly.
Verrica Pharmaceuticals Inc. (VRCA) reported an insider purchase by its Chief Medical Officer. On 11/25/2025, the CMO acquired 2,357 shares of common stock in an open market purchase at a price of $4.2425 per share, and now directly owns 2,357 common shares.
The filing also reports a derivative transaction involving a Series C warrant with an exercise price of $6.315. The warrant covers 589 shares of common stock, is immediately exercisable, and expires on 11/25/2030. The securities were purchased as part of 2,357 investment units, each consisting of one share of common stock and a Series C warrant for one fourth of a share. The warrant includes a 9.99% beneficial ownership limitation, preventing exercises that would push the holder above that ownership level.
Verrica Pharmaceuticals Inc. (VRCA) reported an insider purchase by its Interim CFO. On 11/25/2025, the executive bought 3,536 shares of common stock at $4.2425 per share, bringing their directly held common stock to 8,962 shares after the transaction.
The filing also reports acquisition of 884 Series C warrants with an exercise price of $6.315 per share, exercisable immediately until 11/25/2030, each warrant linked to common stock. All security amounts reflect a 1-for-10 reverse stock split effective July 24, 2025. The Series C warrants include a 9.99% beneficial ownership cap, limiting how many shares can be obtained through exercise relative to the company’s outstanding common stock.
Verrica Pharmaceuticals Inc. (VRCA) disclosed that its Chief Operating Officer filed a Form 4 reporting the purchase of 10,000 shares of common stock on 11/25/2025 at $4.2425 per share through investment units.
Each unit also included a Series C warrant, giving the right to buy one fourth of a share, resulting in warrants exercisable for 2,500 shares of common stock at an exercise price of $6.315, expiring on 11/25/2030. Following the transaction, the officer beneficially owned 21,000 shares of common stock and 2,500 Series C warrants. The warrants are immediately exercisable but contain a 9.99% beneficial ownership limitation, preventing exercises that would push the holder’s ownership above that level. The numbers reflect a 1-for-10 reverse stock split effective July 24, 2025.
Verrica Pharmaceuticals Inc. (VRCA) CEO, President and director reported a personal purchase of 94,311 investment units on 11/25/2025. Each unit includes one share of common stock and a Series C warrant to buy one fourth of a share, at a unit price of $4.2425.
The filing shows direct beneficial ownership of 182,593 common shares after the transaction, adjusted for a 1-for-10 reverse stock split effective July 24, 2025. The related Series C warrants cover 23,577 underlying common shares at an exercise price of $6.315 and are immediately exercisable, subject to a 9.99% beneficial ownership cap. Small additional holdings are reported indirectly through a child and family trusts.
Verrica Pharmaceuticals Inc. (VRCA) director and 10% owner Paul B. Manning reported large purchases of common stock and warrants. On 11/25/2025, he bought 1,375,380 investment units at $4.2425 per unit directly and 2,750,762 units indirectly through BKB Growth Investments, LLC. Each unit consists of one share of common stock and a Series C warrant to buy one fourth of a share at an exercise price of $6.315 per share, exercisable until 11/25/2030.
After these transactions, he beneficially owns millions of shares through direct holdings, BKB, family trusts and an investment entity, with some positions reported as disclaimed beneficial ownership. The Series C warrants are immediately exercisable but include a 49.99% beneficial ownership limitation, meaning they cannot be exercised to push his ownership above 49.99% of Verrica’s outstanding common stock after exercise. The reported share counts have been adjusted for Verrica’s 1-for-10 reverse stock split effective July 24, 2025.